scholarly journals Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns?

2016 ◽  
Vol 52 (1) ◽  
pp. 144-146 ◽  
Author(s):  
W K Cho ◽  
M B Ahn ◽  
J-W Lee ◽  
N-G Chung ◽  
M H Jung ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Bone Mineral ◽  
Steroid Therapy ◽  
Mineral Density ◽  
Hematopoietic Stem

scholarly journals Mandibular radiomorphometric assessment of bone mineral density in survivors of pediatric hematopoietic stem-cell transplantation

Clinics ◽  
2019 ◽  
Vol 74 ◽  
Author(s):  
Alexandre Viana Frascino ◽  
Claudio Costa ◽  
Daniela Miranda Richarte de Andrade Salgado ◽  
Fabio Luiz Coracin ◽  
Marcelo Fava ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Bone Mineral ◽  
Mineral Density ◽  
Hematopoietic Stem

scholarly journals Pre-sarcopenia and bone mineral density in adults submitted to hematopoietic stem cell transplantation

2017 ◽  
Vol 39 (4) ◽  
pp. 343-348 ◽  
Author(s):  
Cristiane Pavan Pereira ◽  
Denise Johnsson Campos Amaral ◽  
Vaneuza Araujo Moreira Funke ◽  
Victória Zeghbi Cochenski Borba
Keyword(s):  
Bone Mineral Density ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Bone Mineral ◽  
Mineral Density ◽  
Hematopoietic Stem

scholarly journals Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients

2020 ◽  
Vol 2020 ◽  
pp. 1-6 ◽  
Author(s):  
Chaiho Jeong ◽  
Hee-Je Kim ◽  
Seok Lee ◽  
Moo Il Kang ◽  
Jeonghoon Ha
Keyword(s):  
Bone Mineral Density ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Bone Mineral ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Solid Organ ◽  
Mineral Density ◽  
Hematopoietic Stem

Purpose. Denosumab is a monoclonal antibody that prevents the development of osteoclasts. The effect of denosumab in solid organ transplant recipients has been elucidated, but its effect in haematopoietic stem cell transplantation recipients has not been studied yet. The aim of this study was to determine the effectiveness and safety of denosumab in haematopoietic stem cell transplantation recipients. Methods. We retrospectively evaluated 33 female patients with osteoporosis (mean age 52.6 ± 9.8 years) following allogeneic haematopoietic stem cell transplantation. Patients were treated with denosumab every 6 months for 12 months. Changes in bone mineral density were evaluated for denosumab-treated patients in a 12-month interval after the first administration of denosumab. Results. Significant increases in bone mineral density were observed in all measured skeletal sites including 4.39 ± 6.63% in the lumbar spine (p=0.014), 3.11 ± 7.69% in the femoral neck (p=0.048), and 1.97 ± 6.01% in the total hip (p=0.138). The bone turnover marker serum cross-linked C-terminal telopeptide of type 1 collagen was decreased at 18 months (−51.6 ± 17.6%, p<0.001). No serious symptomatic hypocalcaemia was observed. Serious adverse drug reactions requiring drug discontinuation were not observed. Conclusion. Denosumab improved bone mineral density in haematopoietic stem cell transplantation recipients. The use of denosumab could be a good therapeutic option without causing severe adverse effects in recipients of haematopoietic transplantation.

Sign in / Sign up

Export Citation Format

Share Document